Overview

Fingolimod -Response According to Coping - Evaluation

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride